================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 27, 2008
NEKTAR THERAPEUTICS
(Exact name of Registrant as specified in its charter)
Delaware 0-24006 94-3134940
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
201 Industrial Road
San Carlos, California 94070
(Address of principal executive offices and Zip Code)
Registrant's telephone number, including area code: (650) 631-3100
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
================================================================================
Item 2.02 Results of Operations and Financial Position
On February 27, 2008, Nektar Therapeutics issued a press release (the
"Press Release") announcing its financial results for the quarter and year ended
December 31, 2007. A copy of the Press Release is furnished herewith as Exhibit
99.1
The information in this report, including the exhibit hereto, is being
furnished and shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of
1933, as amended. The information contained herein and in the accompanying
exhibit shall not be incorporated by reference into any filing with the
Securities and Exchange Commission made by Nektar Therapeutics, whether made
before or after the date hereof, regardless of any general incorporation
language in such filing.
On February 21, 2008, the company announced that it would hold a conference
call on February 27, 2008 to review financial results for the quarter and year
ended December 31, 2007. On this conference call, management expects to make
certain forward-looking statements regarding the market potential and revenue
potential to the company for the company's partnered product programs and
management's corporate objectives and financial guidance for 2008. These
forward-looking statements involve substantial risks and uncertainties including
but not limited to: (i) the market sizes and revenue potential of partnered
product programs are management's estimates only and actual results may differ
materially; (ii) the overall market size for the partnered product programs and
revenue and profit contribution potential to the company will depend upon
successful sales and marketing efforts by our partners, competition from
competing therapies (if any), government and private insurance reimbursement,
changing standards of care, commercial product profile and final product
pricing; (iii) the timing or success of the commencement or end of clinical
trials and commercial launch of partnered products may be delayed or
unsuccessful due to slower than anticipated patient enrollment, drug
manufacturing challenges, clinical outcomes, or delay or failure in obtaining
regulatory approval in one or more important markets; (iv) clinical trials are
long, expensive and uncertain processes and the risk of failure of any product
that is in clinical development and prior to regulatory approval remains high
and can occur at any stage due to efficacy, safety or other factors; (v)
management's financial projections for the company's 2008 revenue and cash used
in operations are subject to the risk of unplanned revenue short-falls or
unanticipated expenses which could adversely affect the company's financial
results and cash position; and (vi) certain other risks and uncertainties set
forth in the company's Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission on November 8, 2007 and its most recent Annual Report on
Form 10-K.
Item 9.01 Financial Statements and Exhibits
Exhibit No. Description
99.1 Press release titled "Nektar Therapeutics Announces Fourth Quarter
And Year-End 2007 Financial Results" issued on February 27, 2008.
================================================================================
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
By: /s/ Gil M. Labrucherie
-----------------------------------------
Gil M. Labrucherie
General Counsel and Secretary
Date: February 27, 2008